HSCI

Successful Results Using Sernova’s Cell Pouch System™ with Evotec’s iPSC-Derived Islet-like Clusters for Type 1 Diabetes Presented at the 4th IPITA / HSCI / JDRF Summit

Retrieved on: 
Monday, April 24, 2023

The objective of the partnership is to produce an off-the-shelf, commercially scalable cell therapy treatment, with human testing anticipated to begin in 2024.

Key Points: 
  • The objective of the partnership is to produce an off-the-shelf, commercially scalable cell therapy treatment, with human testing anticipated to begin in 2024.
  • The presentation included an introduction to Evotec’s proprietary GMP process for manufacturing iPSC-derived ILCs for use in Sernova’s Cell Pouch, as well as encouraging results from multiple studies using a standard mouse model of T1D.
  • ILCs implanted into Sernova’s Cell Pouch demonstrated rapid normalization of glycemic control in the streptozotocin (STZ)-induced diabetic NSG (NOD.SCID.IL-2Rgammanull) mouse model.
  • “These results demonstrate that Evotec’s ILCs in the Cell Pouch can become fully functional endocrine islets following implantation, with potency equivalent to human islets.

EQS-News: Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit

Retrieved on: 
Thursday, March 16, 2023

The presentation will be given by Matthias Austen, PhD, SVP Cell Therapy at Evotec SE (FSE:EVT; NASDAQ:EVO).

Key Points: 
  • The presentation will be given by Matthias Austen, PhD, SVP Cell Therapy at Evotec SE (FSE:EVT; NASDAQ:EVO).
  • Evotec has developed a scalable and comprehensive process for GMP manufacturing of ILCs from a human GMP-grade induced pluripotent stem cell (iPSC) line for cell therapy treatment of insulin-dependent diabetes.
  • In 2022, Evotec entered into a collaboration with Sernova Corp., which has developed the proprietary Cell Pouch System™.
  • Following implantation, the Cell Pouch develops a vascularized environment to support engraftment and long-term function of therapeutic cells.

Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit

Retrieved on: 
Tuesday, March 14, 2023

The presentation will be given by Matthias Austen, PhD, SVP Cell Therapy at Evotec SE.

Key Points: 
  • The presentation will be given by Matthias Austen, PhD, SVP Cell Therapy at Evotec SE.
  • Evotec has developed a scalable and comprehensive process for GMP manufacturing of ILCs from a human GMP-grade induced pluripotent stem cell (iPSC) line for cell therapy treatment of insulin-dependent diabetes.
  • In 2022, Evotec entered into a collaboration with Sernova Corp., which has developed the proprietary Cell Pouch System™.
  • Following implantation, the Cell Pouch develops a vascularized environment to support engraftment and long-term function of therapeutic cells.

Through Huitongda Network (09878) Interim Statement: On the upswing against the trend, "Two Ends with One Road" Initiative promotes persistent progress

Retrieved on: 
Thursday, August 25, 2022

Under such circumstance, Huitongda Network, known as the "No.1 stock in the sunken market", has successfully achieved contrarian growth.

Key Points: 
  • Under such circumstance, Huitongda Network, known as the "No.1 stock in the sunken market", has successfully achieved contrarian growth.
  • Specifically, in the new energy field, Huitongda Network is positioned as a regional operator jointly cooperating with automobile OEMs.
  • Taken together, the general trend of sunken market development has created favorable external conditions for the business development of Huitongda Network.
  • The global capital market rising volatility, it may be the best strategy for investors to continue seizing high-quality growth stocks like Huitongda Network.

JDRF Announces the Appointment of David M. Harlan, MD, as Director of the JDRF Center of Excellence in New England

Retrieved on: 
Thursday, June 16, 2022

To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception.

Key Points: 
  • To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception.
  • We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D.
  • For more information, please visit jdrf.org or follow us on Twitter (@JDRF), Facebook (@myjdrf), and Instagram (@jdrfhq).
  • UMass Chan Medical School , one of five campuses of the University of Massachusetts system, comprises the T.H.

PANCRYOS ANNOUNCES EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR FIRST IN CLASS MACROENCAPSULATION DEVICE

Retrieved on: 
Tuesday, May 24, 2022

COPENHAGEN, Denmark, May 24, 2022 /PRNewswire/ -- Pancryos today announced that it has executed a global exclusive license with Brigham and Women's Hospital for the first in class convection-enhanced macroencapsulation device (ceMED), developed in conjunction with the Harvard Stem Cell Institute (HSCI), which will be the delivery mechanism for the Company's stem cell derived, natural insulin production therapy, PanINSULATM, for the treatment of Type 1 Diabetes.

Key Points: 
  • Primary funding and support were provided by JDRF, the leading global type 1 diabetes research and advocacy organization.
  • "The Pancryos team is excited to be taking this critical next step towards advancing the promise of our innovation and technology," said Jacqueline Ameri, Co-Founder and CEO.
  • This exclusive license puts Pancryos in a unique position to deliver our high-quality beta cells with the innovative ceMED device that will protect the cells from immune-attack.
  • Pancryos was spun out from the Novo Nordisk Foundation Center for Stem Cell Biology at the University of Copenhagen.

PANCRYOS ANNOUNCES EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR FIRST IN CLASS MACROENCAPSULATION DEVICE

Retrieved on: 
Tuesday, May 24, 2022

COPENHAGEN, Denmark, May 24, 2022 /PRNewswire/ -- Pancryos today announced that it has executed a global exclusive license with Brigham and Women's Hospital for the first in class convection-enhanced macroencapsulation device (ceMED), developed in conjunction with the Harvard Stem Cell Institute (HSCI), which will be the delivery mechanism for the Company's stem cell derived, natural insulin production therapy, PanINSULATM, for the treatment of Type 1 Diabetes.

Key Points: 
  • Primary funding and support were provided by JDRF, the leading global type 1 diabetes research and advocacy organization.
  • "The Pancryos team is excited to be taking this critical next step towards advancing the promise of our innovation and technology," said Jacqueline Ameri, Co-Founder and CEO.
  • This exclusive license puts Pancryos in a unique position to deliver our high-quality beta cells with the innovative ceMED device that will protect the cells from immune-attack.
  • Pancryos was spun out from the Novo Nordisk Foundation Center for Stem Cell Biology at the University of Copenhagen.

Wayne A. Marasco, M.D., Ph.D. joins Invectys’ Scientific Advisory Board

Retrieved on: 
Wednesday, March 9, 2022

He is the Scientific Founder Caladrius Biosciences and Chairman of Scientific Advisory Board of several biotechnology companies that have licensed his antibody and cellular therapies for clinical development including Checkpoint Therapeutics, BioRestorative Therapies, Tizona, and AbViro, LLC.

Key Points: 
  • He is the Scientific Founder Caladrius Biosciences and Chairman of Scientific Advisory Board of several biotechnology companies that have licensed his antibody and cellular therapies for clinical development including Checkpoint Therapeutics, BioRestorative Therapies, Tizona, and AbViro, LLC.
  • We are thrilled to see Dr. Marascos bring his skills and experience to our scientific advisory team.
  • We look forward to a fruitful collaboration, commented Praveen Tyle, Ph.D., President, CEO and Board member of Invectys Inc.
    We are delighted to add Wayne Marasco and his formidable expertise in antibody engineering to Invectys SAB, added Maurizio Zanetti, M.D., Chair of Invectys Scientific Advisory Board.
  • Invectys has two wholly owned subsidiaries, Invectys, SAS (Paris) which is focused on scientific research and innovation and Invectys USA, Inc. (Houston) which is directing the clinical development of the Companys lead HLA-G product.

Clover Selected for Inclusion on the Hang Seng Composite Index

Retrieved on: 
Thursday, February 24, 2022

(Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that it has been selected for inclusion in the Hang Seng Composite Index as a constituent stock, effective March 7, 2022.

Key Points: 
  • (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that it has been selected for inclusion in the Hang Seng Composite Index as a constituent stock, effective March 7, 2022.
  • The Hang Seng Composite Index (HSCI) offers a comprehensive Hong Kong market benchmark that covers about 95% of the total market capitalization of companies listed on the Main Board.
  • We are pleased to be added as a constituent stock on the Hang Seng Composite Index.
  • Clover created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavaxs (Nasdaq: DVAX) CpG 1018 advanced adjuvant and aluminum hydroxide (alum).

EC Healthcare Included in the Hang Seng Composite Index & Hang Seng Stock Connect Hong Kong Index

Retrieved on: 
Friday, February 18, 2022

The HSCI inclusion also implies that the Company are eligible stocks for Stock Connect, which is an important scheme for mutual stock market access between the Mainland and Hong Kong.

Key Points: 
  • The HSCI inclusion also implies that the Company are eligible stocks for Stock Connect, which is an important scheme for mutual stock market access between the Mainland and Hong Kong.
  • As EC Healthcare becomes eligible stocks for Stock Connect, the mainland investors can directly trade the Company's stock.
  • Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "The inclusion of EC Healthcare in the Hang Seng Composite Index demonstrates the capital market's recognition of the Group's growth potential.
  • The Group is a constituent stock of the MSCI Small Cap Index and the Hang Seng Composite Index.